• Cynata gets Notice of Allowance from US Patent Office
  • Proteomics secures patent in Hong Kong
  • Ramsay Healthcare and Avita gave solid quarterly updates

Cynata and Proteomics’ patents update

Cynata Therapeutics (ASX:CYP) rose 8pc this morning after receiving a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application covering its proprietary Cymerus mesenchymal stem cell (MSC) platform technology.

Cynata had earlier submitted a patent application entitled “Pluripotent Stem Cell Assay”.

The patent is wholly owned by Cynata, and describes a novel method for ensuring quality and purity of Cynata’s finished therapeutic MSC products.

A Notice of Allowance is usually sent to the applicant when the USPTO intends to issue a patent.

This patent is expected to add to the existing IP protection of the Cymerus manufacturing platform, and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products.

“This important achievement adds to our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2037 and beyond,” said Cynata CEO, Dr Kilian Kelly.

Proteomics International (ASX:PIQ) meanwhile has also secured a patent for its PromarkerD predictive test for diabetic kidney disease in Hong Kong.

The patent joins those already granted for the US, Europe, Australia, Brazil, Canada, China, Indonesia, Russia, Singapore, India and Japan.

The PromarkerD intellectual property portfolio now covers 64% of the global population living with diabetes.

“Hong Kong is an important gateway market and there is the potential for PromarkerD testing to be introduced there prior to entering the much larger China market,” said Proteomics’ CEO, Dr Richard Lipscombe.

Ramsay and Avita gave quarterly updates

Private hospital network company Ramsay Healthcare (ASX:RHC) has issued a Q1 FY23 business update earlier this morning.

Activity levels have improved across all regions over the course of Q1 compared to the pcp.

Total revenue for the quarter was $3.445 billion, a 6.7% uptick from the pcp.

Net profit was $57.4 million, down 1.2% from the pcp.

Ramsays its outlook remains strong as the business is well placed to take advantage of the positive long-term dynamics driving the healthcare industry.

Ramsay expects a gradual recovery through FY23, and more normalised conditions from FY24.

Avita Medical (ASX:AVH) has also reported its Q3 FY22 revenue this morning.

Reported total revenue was $9.1 million, compared to $7 million in the pcp.

Gross profit margin was 83%.

Other highlights in the quarter include the encouraging topline results from its pivotal randomised controlled trial of the RECELL System for healing of soft tissue repair with reduced donor skin.

During the quarter, Avita also received a Breakthrough Device designation from the FDA for the RECELL System for soft tissue repair and vitiligo.

Resonance signs two more clinical trial service deals

Resonance Health (ASX:RHT) has been contracted to provide services for two new pharma customers in their clinical trials.

Value of the new contracts is up to $1.5m (€1m), payable over the 28-month duration of each trial.

Resonance Health will provide its FerriScan and Cardiac-T2 iron-overload analysis and related services.

Today’s agreement increases the total clinical trials currently under contract and being serviced by Resonance Health to 12.


Share prices today: